Johnson & Johnson announced launch of VARIPULSE Pro in Europe following CE Mark approval, further advancing its pulsed field ...
Johnson & Johnson today announced positive 12-month interim effectiveness and safety results from a study of its Varipulse ...
Clinical Evidence Further Demonstrates Efficacy and Accuracy of VIVO for Ventricular ProceduresFORT MILL, S.C., April 13, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) (“VTAK ...
Pulse Biosciences (Nasdaq:PLSE) announced today that it enrolled the first patients in its NANOPULSE-AF study.
The Varipulse Pro pulsed field ablation platform, which has received a CE mark, will be a focus at the upcoming European ...
U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary ...
The successful start of these two studies demonstrates the versatility of the VERAFEYE™ platform guiding ablation workflows entirely through live intra-procedural imaging (2D and 4D), and precise ...
DUBLIN, March 19, 2026 /PRNewswire/ -- LUMA Vision, a leader in cardiac 4D imaging and navigation, today announces the expansion of its clinical program with the first patient enrolments in two ...
Stereotaxis STXS recently announced that the FDA granted 510(k) clearance for its Synchrony system, a next-generation ...
From its first use in 1998, to its status as a routine management strategy when medication is not an option, our understanding of catheter ablation for AF has grown immensely 4. Over the past 28 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results